Citations 1-10 of 715 total displayed.

News

More than half of drugs sold online are fake or substandard

Susan Mayor

BMJ 2008;337:a618, doi: 10.1136/bmj.a618, (Published 2 July 2008)

[Extract] [Full text]  

Editorials

Drugs for cancer and copayments

Ilora Finlay and Nigel Crisp

BMJ 2008;337:a527, doi: 10.1136/bmj.a527, (Published 30 June 2008)

[Extract] [Full text]  

News

Government and industry reach new pricing deal to cut NHS drugs bill

Andrew Jack

BMJ 2008;336:1455, doi: 10.1136/bmj.a464, (Published 28 June 2008)

[Extract] [Full text] [PDF]  

News

Drug maker’s PR firm is force behind blood clot awareness campaign

Ray Moynihan

BMJ 2008;336:1460, doi: 10.1136/bmj.a502, (Published 28 June 2008)

[Extract] [Full text] [PDF]  

News

Personalised medicine requires regulatory change, former FDA head says

Bob Roehr

BMJ 2008;336:1461, doi: 10.1136/bmj.a537, (Published 28 June 2008)

[Extract] [Full text]  

News

Europe’s drug companies are better than those in US in making drugs accessible to poor countries

Andrew Jack

BMJ 2008;336:1396, doi: 10.1136/bmj.a397, (Published 21 June 2008)

[Extract] [Full text] [PDF]  

Feature

Key opinion leaders: independent experts or drug representatives in disguise?

Ray Moynihan

BMJ 2008;336:1402, doi: 10.1136/bmj.39575.675787.651, (Published 21 June 2008)

[Extract] [Full text] [PDF]  

Head to Head

Should the drug industry work with key opinion leaders? Yes

Charlie Buckwell

BMJ 2008;336:1404, doi: 10.1136/bmj.39541.702870.59, (Published 21 June 2008)

[Extract] [Full text] [PDF]  

Head to Head

Should the drug industry work with key opinion leaders? No

Giovanni A Fava

BMJ 2008;336:1405, doi: 10.1136/bmj.39541.731493.59, (Published 21 June 2008)

[Extract] [Full text] [PDF]  

News

US branded drug makers pay to prevent generic competition

Janice Hopkins Tanne

BMJ 2008;336:1266, doi: 10.1136/bmj.39601.618241.DB, (Published 7 June 2008)

[Extract] [Full text] [PDF]